| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 21(1); 1989 > Article
Journal of the Korean Cancer Association 1989;21(1): 82-93.
진행성 비소세포 폐암에 대한 Cisplatin , Etoposide , Vinblastine ( PEV ) 3 제 복합 화학 요법
박근칠, 강윤구, 신동복, 김시영, 방영주, 한성구, 심영수, 김노경, 김건열, 한용철
Combination Chemotherapy with Cisplatin , Etoposide , and Vinblastine ( PEV ) in the Advanced Non - Small Cell Lung Cancer
Keun Chil Park, Yoon Koo Kang, Dong Bok Shin, Si Young Kim, Yung Jue Bang, Sung Koo Han, Young Soo Shim, Noe Kyeong Kim, Keun Youl Kim, Keun Youl Kim
Fifty patients with the advanced non-small cell lung cancer, who had no previous treatment, were treated with a combination chemotherapy regimen consisting of cisplatin (20mg/m i.v. day 1-5), etoposide (100 mg/m i.v. day 2-4), and vinblastine (6 mg/m(2) i.v, day 1) every 3 weeks. Among the 50 patients entered into this study 45 patients were evaluable for response. Objective responses were achieved in 49 % (22/45) of patients (2 CRs, 20 PRs). In 23 patients with limited disease, the response rate was 61% (14/23) with no complete response, higher than that, but not statistically significant, in the extensive disease patients (36% with 2 CRs). The overall median survival of the patients was 42.6 weeks and the responding patients survived longer than non-responders (median survival; 51.5 weeks vs. 37.4 weeks, p<0.05). Toxicity with this regimen was acceptable; myelosup- pression was the major toxic effect and was severe in only 11% of the patients with one treatment- related death from sepsis associated with granulocytopenia. The gastrointestinal side effects and alopecia were rather universal and the peripheral neuropathy (20%) and azotemia (9%) were not uncommon, but manageable in general.
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI